Literature DB >> 7679825

Adverse effects of FK 506 overdosage after liver transplantation.

M Alessiani1, U Cillo, J J Fung, W Irish, K Abu-Elmagd, A Jain, S Takaya, D Van Thiel, T E Starzl.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 7679825      PMCID： PMC2996874     

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  29 in total

Review 1.  The spectrum of ciclosporin nephrotoxicity.

Authors:  J B Puschett; A Greenberg; J Holley; J McCauley
Journal:  Am J Nephrol       Date:  1990       Impact factor: 3.754

2.  A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine.

Authors:  J Fung; K Abu-Elmagd; A Jain; R Gordon; A Tzakis; S Todo; S Takaya; M Alessiani; A Demetris; O Bronster
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

3.  Neurologic complications of FK 506.

Authors:  B H Eidelman; K Abu-Elmagd; J Wilson; J J Fung; M Alessiani; A Jain; S Takaya; S N Todo; A Tzakis; D Van Thiel
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

Review 4.  Adverse effects associated with the use of FK 506.

Authors:  J J Fung; M Alessiani; K Abu-Elmagd; S Todo; R Shapiro; A Tzakis; D Van Thiel; J Armitage; A Jain; J McCauley
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

Review 5.  Immunophilin-ligand complexes as probes of intracellular signaling pathways.

Authors:  S L Schreiber; J Liu; M W Albers; R Karmacharya; E Koh; P K Martin; M K Rosen; R F Standaert; T J Wandless
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

6.  Four-hour versus 24-hour intravenous infusion of FK 506 in liver transplantation.

Authors:  K M Abu-Elmagd; J Fung; R Draviam; W Shannon; A Jain; M Alessiani; S Takaya; R Venkataramanan; V S Warty; A Tzakis
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

7.  Studies on mechanisms of augmentation of liver regeneration by cyclosporine and FK 506.

Authors:  A Francavilla; T E Starzl; M Barone; Q H Zeng; K A Porter; A Zeevi; P M Markus; M R van den Brink; S Todo
Journal:  Hepatology       Date:  1991-07       Impact factor: 17.425

8.  The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver.

Authors:  K Abu-Elmagd; J J Fung; M Alessiani; A Jain; R Venkataramanan; V S Warty; S Takaya; S Todo; W D Shannon; T E Starzl
Journal:  Transplantation       Date:  1991-07       Impact factor: 4.939

9.  The effect of bile duct ligation and bile diversion on FK506 pharmacokinetics in dogs.

Authors:  H Furukawa; O Imventarza; R Venkataramanan; M Suzuki; Y Zhu; V S Warty; J Fung; S Todo; T E Starzl
Journal:  Transplantation       Date:  1992-04       Impact factor: 4.939

10.  Long-term use of cyclosporin in liver grafting.

Authors:  R Williams; A Blackburn; J Neuberger; R Y Calne
Journal:  Q J Med       Date:  1985-12
View more
  19 in total

1.  Vasorelaxation and inhibition of the voltage-operated Ca2+ channels by FK506 in the porcine coronary artery.

Authors:  T Yasutsune; N Kawakami; K Hirano; J Nishimura; H Yasui; K Kitamura; H Kanaide
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 8.739

2.  Daily dosing of tacrolimus in patients treated with HIV-1 therapy containing a ritonavir-boosted protease inhibitor or raltegravir.

Authors:  Markus Bickel; Evrim Anadol; Martin Vogel; Wolf Peter Hofmann; Nils von Hentig; Johannes Kuetscher; Michael Kurowski; Christian Moench; Tessa Lennemann; Thomas Lutz; Wolf Otto Bechstein; Hans Reinhard Brodt; Jürgen Rockstroh
Journal:  J Antimicrob Chemother       Date:  2010-03-04       Impact factor: 5.790

3.  Tacrolimus (FK506)-Associated Renal Pathology.

Authors:  Parmjeet S Randhawa; Thomas E Starzl; Anthony Jake Demetris
Journal:  Adv Anat Pathol       Date:  1997-07       Impact factor: 3.875

4.  Clinical features of acute reversible tacrolimus (FK 506) nephrotoxicity in kidney transplant recipients.

Authors:  S R Katari; M Magnone; R Shapiro; M Jordan; V Scantlebury; C Vivas; A Gritsch; J McCauley; T Starzl; A J Demetris; P S Randhawa
Journal:  Clin Transplant       Date:  1997-06       Impact factor: 2.863

5.  What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term follow-up of the first 1000 patients.

Authors:  A Jain; J Reyes; R Kashyap; S Rohal; K Abu-Elmagd; T Starzl; J Fung
Journal:  Ann Surg       Date:  1999-09       Impact factor: 12.969

6.  Pharmacokinetics of SDZ RAD and cyclosporin including their metabolites in seven kidney graft patients after the first dose of SDZ RAD.

Authors:  G I Kirchner; M Winkler; L Mueller; C Vidal; W Jacobsen; A Franzke; S Wagner; S Blick; M P Manns; K F Sewing
Journal:  Br J Clin Pharmacol       Date:  2000-11       Impact factor: 4.335

Review 7.  A risk-benefit assessment of tacrolimus in transplantation.

Authors:  M Winkler; U Christians
Journal:  Drug Saf       Date:  1995-05       Impact factor: 5.606

Review 8.  FK506 in solid organ transplantation.

Authors:  J J Fung; T E Starzl
Journal:  Ther Drug Monit       Date:  1995-12       Impact factor: 3.681

Review 9.  Clinical pharmacokinetics of tacrolimus.

Authors:  R Venkataramanan; A Swaminathan; T Prasad; A Jain; S Zuckerman; V Warty; J McMichael; J Lever; G Burckart; T Starzl
Journal:  Clin Pharmacokinet       Date:  1995-12       Impact factor: 6.447

10.  Measurement of blood concentrations of FK506 (tacrolimus) and its metabolites in seven liver graft patients after the first dose by h.p.l.c.-MS and microparticle enzyme immunoassay (MEIA).

Authors:  A K Gonschior; U Christians; F Braun; M Winkler; A Linck; J Baumann; K F Sewing
Journal:  Br J Clin Pharmacol       Date:  1994-12       Impact factor: 4.335
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.